NCT00430521 - Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A) | Biotech Hunter

Enrollment

512

Participants

Timeline

Start Date

February 5, 2007

Primary Completion Date

October 20, 2008

Study Completion Date

October 20, 2008

Conditions

InfluenzaInfluenza Vaccines

Interventions

BIOLOGICAL

Pandemic influenza vaccine (GSK1119711A)-formulation 1

2 or 3 doses, intramuscular injection, at different time points.

BIOLOGICAL

Pandemic influenza vaccine (GSK1119711A)-formulation 2

2 or 3 doses, intramuscular injection, at different time points.

Trial Locations (10)

GSK Investigational Site, Berlin

GSK Investigational Site, Schwerin

GSK Investigational Site, Hamburg

GSK Investigational Site, Mainz

GSK Investigational Site, Witten

GSK Investigational Site, Munich

GSK Investigational Site, Neu-Ulm

GSK Investigational Site, Regensburg

GSK Investigational Site, Deggendorf

GSK Investigational Site, Würzburg